BGI-HL OHA Lab Inaugurated in Harbin, Initiating Colorectal Cancer Risk Assessment for 800,000
BGI-HL OHA Lab Inaugurated in Harbin, Initiating Colorectal Cancer Risk Assessment for 800,000
SHENZHEN, China, May 13, 2024 /PRNewswire/ -- On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance in the province's efforts to address public health challenges. Utilizing the '13311i GigaLab' technological framework, this facility supports vital life and health science research, enhancing the region's capacity to produce innovative health solutions.
2024年5月13日，华大基因-黑龙江组学健康轴智能实验室（BGI-黑龙江OHA智能实验室）于中国黑龙江省哈尔滨市落成启用，利用“13311i GigaLab”技术框架，支持重要的生命与健康科学研究，提高了地区创新健康解决方案的能力。
The '13311i' framework is at the forefront of proactive health management, integrating whole genome sequencing with analyses of blood, urine, and fecal samples and sophisticated imaging techniques such as CT, ultrasound, and MRI. With detailed health and disease risk profiles, it sets the stage for breakthroughs in early detection and personalized treatment, critical tenets of precision medicine.
“13311i”框架处于积极健康管理的前沿，整合了全基因组测序与血液、尿液以及粪便样本分析以及高级影像技术，如CT、超声和MRI。该框架通过详细的健康和疾病风险概况，为早期检测和个性化治疗打下了基础，是精准医疗的关键前提。
The opening ceremony featured BGI Group CEO and BGI Genomics Vice Chairman Yin Ye, BGI Genomics Vice President Li Zhiping, and BGI Genomics Northeast Region General Manager Su Hang, along with Heilongjiang Longwei Precision Medicine Laboratory Chairman Jia Lipeng.
开幕式上，出席者包括华大集团CEO兼华大基因副董事长尹烨、华大基因副总裁李志平、华大基因东北地区总经理苏航和黑龙江隆伟精准医疗实验室董事长贾立鹏。
Colorectal cancer, a focal point of the Lab's research, is ranked as the third most common cancer worldwide and the second leading cause of cancer-related deaths. According to the "Global Cancer Statistics 2020" report by the World Health Organization, there were over 1.9 million new cases of CRC and nearly 930,000 deaths in 2020. The Lab's initiatives address this significant health burden with the world's highest throughput sequencer, DNBSEQ-T20×2, enhancing the efficiency and quality of diagnostics.
结直肠癌是实验室研究的一个重点，是全球第三常见的癌症和第二大致死因。根据世界卫生组织2020年的《全球癌症统计数据2020》报告，2020年发生了超过190万份新的CRC病例和近93万份死亡。实验室的举措通过全球最高吞吐量的测序仪DNBSEQ-T20×2，增强了诊断的效率和质量，缓解了这种重要的健康负担。
The laboratory's first significant initiative involves assessing colorectal cancer risks for nearly 800,000 eligible for screening (45-64-year-old residents), employing gene methylation technology for early detection and preventive care. This large-scale public health effort exemplifies the Lab's commitment to precision medicine, tailored to combat public health issues more effectively.
实验室的第一项重要举措涉及评估近80万符合筛查条件的结直肠癌风险（45-64岁居民），采用基因甲基化技术进行早期检测和预防保健。这项大规模的公共卫生工作充分体现了实验室致力于精准医疗，在更有效地应对公共卫生问题方面进行个性化处理。
Yin Ye remarked, "By integrating our latest technologies, we are poised to make significant contributions to global public health, particularly in managing chronic diseases and shaping future medical practices."
尹烨表示：“通过整合我们的最新技术，我们将为全球公共卫生做出重要贡献，尤其是在管理慢性病和塑造未来医学方面。”
The BGI-HL OHA Intelligent Laboratory also spearheads the '13311i' project to develop a comprehensive technical system for disease prevention and health management across the entire population and lifecycle. This project utilizes a genomics-based approach and integrates various data forms, from high-resolution imaging to real-time physiological data collected through wearable devices, ensuring a holistic view of health risks and outcomes.
华大基因-黑龙江OHA智能实验室还领导“13311i”项目，开发一种全面的技术系统，用于预防疾病和健康管理，覆盖整个人口和生命周期。该项目采用基因组学方法，整合各种数据形式，从高分辨率影像到通过可穿戴设备收集的实时生理数据，确保了健康风险和结果的整体视图。
Looking ahead, this Lab plans to broaden its impact through extensive genomic research projects that will benefit public health, precision medicine, and even modern agriculture. This facility is committed to advancing Heilongjiang's digital and biotech ecosystem and contributing to public health improvements by applying the latest life science technologies.
展望未来，这个实验室计划通过广泛的基因组学研究项目扩大其影响，从而使公共卫生、精准医学甚至现代农业获益。该实验室致力于推动黑龙江的数字和生物科技生态系统，通过应用最新的生命科学技术为公共卫生改进做出贡献。
SOURCE BGI Genomics Co., Ltd.
来源 华大基因股份有限公司。